Candel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million
Reuters2026/08/13 12:08- Candel Therapeutics posted a Q2 2026 net loss of USD 38.9 million, widening from a loss of USD 4.8 million.
- RD expense rose to USD 19.8 million from USD 7 million, driven by higher clinical-trial and manufacturing costs.
- GA expense increased to USD 6.9 million from USD 4.2 million on higher commercial-readiness and employee-related costs.
- Cash and cash equivalents climbed to USD 201.6 million at June 30, 2026, with runway expected into Q1 2028.
- Targets a prostate-cancer BLA for aglatimagene in Q4 2026, with a potential U.S. launch in 2027 if approved.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
No Public Money Behind El Salvador’s New Bitcoin, IMF Confirms
Crypto prices
More
